Intraductal breast cancer does not require Herceptin-targeted therapy

Patient.
Patient female, 52 years old had breast-conserving surgery for right breast cancer at the Affiliated Hospital of Inner Mongolia Medical College on June 25, 2012 Pathological diagnosis: 1. (right breast) intraductal carcinoma with infiltration in the cell (grade II) more lymphocytes were seen around. 2. (Right breast 12 and 6 o’clock) adenopathy with ductal dilatation and ductal epithelial hyperplasia, no cancer was seen. 3. (Sentinel lymph nodes) 3 lymph nodes, none of them showed cancer metastasis (0/3). 4. (3.6.9.12 points and basal cut margin) No cancer was seen. P63 cell (-), CK5/6 cell (-), CK high (+), ER (-), PR (-), Cerb-B2 (++), Ki-67 5%+, P53 (-), AR ( -), E-cad (+). FISH results: Her-2 gene amplification (intraductal).
Local doctor suggested to do radiotherapy and then Herceptin. There is no other way. Now in radiotherapy, doctor said 6 weeks of radiotherapy
Since Herceptin is expensive, I would like to consult if there is any other way without Herceptin? Chang Xinzhong, Department of Breast Oncology, Tianjin Cancer Hospital